FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287654439> ?p ?o ?g. }

• W2287654439 endingPage "ix65" @default.
• W2287654439 startingPage "ix65" @default.
• W2287654439 abstract "Background: Neutropenia is a major factor affecting the continuation of chemotherapy for colorectal cancer. In many clinical trials, a neutrophil count of more than 1500 is targeted for the continuation of chemotherapy; for a count of less than 1500, medication is commonly discontinued. However, there is no definite evidence for setting the targeted neutrophil count at 1500. In our department, chemotherapy is discontinued when the neutrophil count is less than 1000 (Grade3); for a count of 1000 to 1500 (Grade2), chemotherapy is continued. We examined the neutrophil count during continuation of chemotherapy in patients with a count of 1000 to 1500, and verified whether these neutrophil counts warrant discontinuation of medication. Moreover, we examined the neutrophil count during the previous course of chemotherapy when it fell below 1000.Methods: The study included 104 patients who received XELOX + bevacizumab (BV) therapy, XELOX therapy, and XELIRI + BV therapy for advanced or recurrent colorectal cancer.Results: The patients with a neutrophil count of 1000 to 1500 were 26 (23.1%) of the total. Two (7.7%) of 26 patients had a neutrophil count of less than 1000 during the following course of chemotherapy. Moreover, among the patients with a neutrophil count of less than 1000, 33.3% had a count of 1000 to 1500 during the previous course of chemotherapy and 66.7% had a count of more than 1500.Conclusions: According to these results, Grade2 neutropenia cannot predict the risk of the Grade3 neutropenia. Continuation of chemotherapy in patients with a neutrophil count of 1000 to 1500 may be appropriate, and discontinuation of therapy is not always required. Background: Neutropenia is a major factor affecting the continuation of chemotherapy for colorectal cancer. In many clinical trials, a neutrophil count of more than 1500 is targeted for the continuation of chemotherapy; for a count of less than 1500, medication is commonly discontinued. However, there is no definite evidence for setting the targeted neutrophil count at 1500. In our department, chemotherapy is discontinued when the neutrophil count is less than 1000 (Grade3); for a count of 1000 to 1500 (Grade2), chemotherapy is continued. We examined the neutrophil count during continuation of chemotherapy in patients with a count of 1000 to 1500, and verified whether these neutrophil counts warrant discontinuation of medication. Moreover, we examined the neutrophil count during the previous course of chemotherapy when it fell below 1000. Methods: The study included 104 patients who received XELOX + bevacizumab (BV) therapy, XELOX therapy, and XELIRI + BV therapy for advanced or recurrent colorectal cancer. Results: The patients with a neutrophil count of 1000 to 1500 were 26 (23.1%) of the total. Two (7.7%) of 26 patients had a neutrophil count of less than 1000 during the following course of chemotherapy. Moreover, among the patients with a neutrophil count of less than 1000, 33.3% had a count of 1000 to 1500 during the previous course of chemotherapy and 66.7% had a count of more than 1500. Conclusions: According to these results, Grade2 neutropenia cannot predict the risk of the Grade3 neutropenia. Continuation of chemotherapy in patients with a neutrophil count of 1000 to 1500 may be appropriate, and discontinuation of therapy is not always required." @default.
• W2287654439 created "2016-06-24" @default.
• W2287654439 creator A5001514470 @default.
• W2287654439 creator A5027714564 @default.
• W2287654439 creator A5039729044 @default.
• W2287654439 creator A5046900502 @default.
• W2287654439 creator A5062939532 @default.
• W2287654439 creator A5090905175 @default.
• W2287654439 creator A5021018726 @default.
• W2287654439 creator A5061447606 @default.
• W2287654439 date "2013-11-01" @default.
• W2287654439 modified "2023-10-14" @default.
• W2287654439 title "Can GRADE2 Neutropenia Predict the Risk of Grade3 Neutropenia in Colorectal Cancer Patients Treated with Chemotherapy?" @default.
• W2287654439 doi "https://doi.org/10.1093/annonc/mdt459.154" @default.
• W2287654439 hasPublicationYear "2013" @default.
• W2287654439 type Work @default.
• W2287654439 sameAs 2287654439 @default.
• W2287654439 citedByCount "0" @default.
• W2287654439 crossrefType "journal-article" @default.
• W2287654439 hasAuthorship W2287654439A5001514470 @default.
• W2287654439 hasAuthorship W2287654439A5021018726 @default.
• W2287654439 hasAuthorship W2287654439A5027714564 @default.
• W2287654439 hasAuthorship W2287654439A5039729044 @default.
• W2287654439 hasAuthorship W2287654439A5046900502 @default.
• W2287654439 hasAuthorship W2287654439A5061447606 @default.
• W2287654439 hasAuthorship W2287654439A5062939532 @default.
• W2287654439 hasAuthorship W2287654439A5090905175 @default.
• W2287654439 hasBestOaLocation W22876544391 @default.
• W2287654439 hasConcept C121608353 @default.
• W2287654439 hasConcept C126322002 @default.
• W2287654439 hasConcept C143998085 @default.
• W2287654439 hasConcept C2776694085 @default.
• W2287654439 hasConcept C2777063308 @default.
• W2287654439 hasConcept C2777802072 @default.
• W2287654439 hasConcept C2778336483 @default.
• W2287654439 hasConcept C2778715236 @default.
• W2287654439 hasConcept C2780873365 @default.
• W2287654439 hasConcept C526805850 @default.
• W2287654439 hasConcept C71924100 @default.
• W2287654439 hasConcept C74133956 @default.
• W2287654439 hasConcept C90924648 @default.
• W2287654439 hasConceptScore W2287654439C121608353 @default.
• W2287654439 hasConceptScore W2287654439C126322002 @default.
• W2287654439 hasConceptScore W2287654439C143998085 @default.
• W2287654439 hasConceptScore W2287654439C2776694085 @default.
• W2287654439 hasConceptScore W2287654439C2777063308 @default.
• W2287654439 hasConceptScore W2287654439C2777802072 @default.
• W2287654439 hasConceptScore W2287654439C2778336483 @default.
• W2287654439 hasConceptScore W2287654439C2778715236 @default.
• W2287654439 hasConceptScore W2287654439C2780873365 @default.
• W2287654439 hasConceptScore W2287654439C526805850 @default.
• W2287654439 hasConceptScore W2287654439C71924100 @default.
• W2287654439 hasConceptScore W2287654439C74133956 @default.
• W2287654439 hasConceptScore W2287654439C90924648 @default.
• W2287654439 hasLocation W22876544391 @default.
• W2287654439 hasOpenAccess W2287654439 @default.
• W2287654439 hasPrimaryLocation W22876544391 @default.
• W2287654439 hasRelatedWork W15091867 @default.
• W2287654439 hasRelatedWork W1530620987 @default.
• W2287654439 hasRelatedWork W1982362071 @default.
• W2287654439 hasRelatedWork W202648080 @default.
• W2287654439 hasRelatedWork W2349181903 @default.
• W2287654439 hasRelatedWork W2430901395 @default.
• W2287654439 hasRelatedWork W2994693882 @default.
• W2287654439 hasRelatedWork W2997510975 @default.
• W2287654439 hasRelatedWork W764687 @default.
• W2287654439 hasRelatedWork W2242454958 @default.
• W2287654439 hasVolume "24" @default.
• W2287654439 isParatext "false" @default.
• W2287654439 isRetracted "false" @default.
• W2287654439 magId "2287654439" @default.
• W2287654439 workType "article" @default.